Keyi Pharma's Dual-Target CAR-T Therapy KQ-2003 Secures Exclusive Licensing Deal in India with VRise Therapeutics

Sep 29, 2025 07:20 CST Updated 07:20

Novatim

Innovative Drug Developer for Tumor Immunotherapy

Free Early Bird Tickets, Limited to 200

September 29, 2025

eMedClub News

September 27, 2025, Novatim（ZheJiang)Pharmaceutical Technology Co., Ltd.(hereinafter referred to as "Novatim")Announced, in collaboration with the U.S.-based biopharmaceutical company VRise Therapeutics(hereinafter referred to as「VRise」)Reached a strategic cooperation, and both parties signed an agreement regarding Novatim's independently developed...World's First Parallel-Enhanced Dual-Targeting CAR-T Cell Therapy Product KQ-2003(Targeting BCMA/CD19)Exclusive Regional Licensing Agreement for IndiaVRise will obtain the exclusive rights for the development, registration, and commercialization of this product in the Indian region. In addition to advancing the indication for relapsed/refractory multiple myeloma, VRise will alsoPlan to Explore KQ-2003 for the Treatment of Autoimmune Diseases in the Indian RegionClinical and Commercial Potential.

According to the terms of the agreement, Novatim will receive an upfront payment and milestone payments during the R&D, registration, and commercialization phases. In addition, Novatim will also be entitled to tiered royalties in the high single-digit to double-digit percentage range based on the net sales of KQ-2003 within the licensed territory.

Significance of Cooperation: Further Accelerate the Monetization of Commercial Value

KQ-2003 is currently in Phase I/IIa clinical trials in China. Previously, Erigen had obtained the rights to this product outside of Greater China.(Excluding India, Turkey, Russia)The development and commercialization authorization. This new authorization further confirms the global recognition of the development potential and market value of KQ-2003. With the clinical trials and fast-track market entry mechanisms in India, KQ-2003 is expected to be launched in India first, providing local patients with a new treatment option and accelerating Novatim's realization of commercial returns.

About KQ-2003

KQ-2003 is an innovative therapy developed by Novatim based on its enhanced dual-target CAR-T platform. Through a parallel structural design and optimization of the signaling domain, it significantly enhances the persistence and anti-tumor activity of CAR-T cells while reducing the risk of relapse associated with traditional CAR-T therapies. Its core advantages include: excellent efficacy, safety benefits, and cost competitiveness. It is currently being applied in relapsed/refractory multiple myeloma.（rrMM）and POEMS syndrome, etc., have achieved exciting efficacy in registrational clinical trials.

Exciting Live Broadcast Preview

Press and hold to scan the QR code and participate immediately ↓

Recommendation 1

September 29, 15:00-16:00

Small Preferred Products | Ultra-Practical Guide to Cell Culture

Statement:This article aims to convey industry development information and explore the frontier progress of biomedicine. The content of the article only represents the author's viewpoint, and does not represent the position of Eureka Biomedical, nor does it constitute any value judgment, investment advice, or medical guidance. If necessary, please consult a professional for investment or visit a regular hospital for medical advice.

Copyright Statement:Welcome to share the article on your personal Moments, but unauthorized media or organizations are prohibited from reprinting it on other platforms in any form. If you need to reprint, please leave a message under the article to obtain authorization.

Cover image source: internet. If there is any copyright infringement, please contact us for removal.

Dian Dian "Share”、“Like" and "In View"，Give me a little recharge~